Introduction
============

Inhibition of nitric oxide (NO) synthesis is currently investigated for the treatment of hypotension associated with septic shock. Since both endotoxin (ETX) and NO have been reported to influence gluconeogenesis we compared the effects of standard vasopressor therapy with noradrenaline (NOR) to L-NMMA on endogenous glucose release during long-term ETX induced shock.

Methods
=======

Pigs were studied in a normotensive, hyperdynamic shock model with volume resuscitation (HES 6%) to keep intrathoracic blood volume constant. Animals were randomly assigned to three groups 12 h after start of ETX infusion. ETX group: no drug treatment (*n* = 8); NOR group: treatment with NOR (*n* = 11); L-NMMA group: treatment with L-NMMA (*n* = 11), both titrated to maintain MAP at preshock levels. Hepatic uptake of glucose precursors as well as endogenous glucose formation (stable isotope approach) were measured.

Results
=======

Data are median and interquartile range. \**P* \< 0.05 vs preshock (RM ANOVA on ranks).\*\**P* \< 0.05 between groups (ANOVA).

Conclusion
==========

Despite their similar effects on liver hemodynamics and O~2~ kinetics neither NOR nor L-NMMA influenced the ETX-induced dissociation between liver uptake rates of glucose precursors and total *de novo* glucose formation rate.

                                    Preshock       12 h            18 h                 24 h
  -------------------- ------------ -------------- --------------- -------------------- ---------------
  Liver lactate        ETX^\*^      13 \[11;17\]   5 \[-1;8\]      2 \[-3;5\]           -6 \[-16;5\]
  uptake               NOR^\*^      9 \[6;16\]     -2 \[-7;4\]     -4 \[-11;3\]         -5 \[-10;6\]
  (μmol/min/kg)        L-NMMA^\*^   9 \[7;14\]     3 \[0;4\]       -8 \[-10;-4\]        -17 \[-24;9\]
  Endogenous glucose   ETX^\*^      25 \[20;28\]   32 \[29;38\]    32 \[22;39\]         36 \[29;65\]
  production           NOR^\*^      23 \[20;24\]   34 \[31 ;37\]   43 \[36;50\]^\*\*^   35 \[28;49\]
  (μmol/min/kg)        L-NMMA^\*^   23 \[18;26\]   30 \[27;35\]    26 \[25;43\]         29 \[23;33\]
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